Infinity Pharmaceuticals, Inc. (INFI)
(Delayed Data from NSDQ)
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.71 USD
+0.06 (3.64%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.72 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
WellCare and Catholic Health Team Up to Improve Health Care
by Zacks Equity Research
WellCare of New York, Inc., a wholly owned subsidiary of WellCare Health Plans, Inc. (WCG), recently inked a deal with Catholic Health and Catholic Medical Partners to enhance its health care services.
Community Health Completes Tender Offer for Senior Notes
by Zacks Equity Research
Community Health Systems, Inc. (CYH) recently announced the completion of the previously announced cash tender offer for its outstanding 5.125% Senior Secured Notes, due 2018.
What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?
by Zacks Equity Research
Valeant Pharmaceuticals (VRX) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.
Should You Get Rid of Patheon (PTHN) Now?
by Zacks Equity Research
Patheon (PTHN) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
What Makes Tesaro (TSRO) a Strong Sell?
by Zacks Equity Research
Tesaro (TSRO) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock?
by Zacks Equity Research
Investors in Infinity Pharmaceuticals, Inc. (INFI) need to pay close attention to the stock based on moves in the options market lately.
3 Reasons Why Infinity Pharmaceuticals (INFI) is a Great Momentum Stock
by Zacks Equity Research
If you are looking for a fresh pick that has potential to move in the right direction, definitely keep Infinity Pharmaceuticals (INFI) on your short list as this looks be a stock that is very well-positioned to soar in the near term.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
by Zacks Equity Research
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.
Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.
Not Too Late to Ride on Q4 Earnings: 3 Biotech Picks
by Zacks Equity Research
The biotech sector continues to witness a flurry of mergers and acquisitions and licensing deals.